SLC5A2 and type 2 diabetes mellitus: Therapies targeting gut pathways (like GLP-1 receptor agonists, SGLT2 inhibitors, or even bariatric surgery) have delivered some of the most significant advances in T2D outcomes, validating the importance of Gut-X axes.